J
Jan J. Cornelissen
Researcher at Erasmus University Rotterdam
Publications - 433
Citations - 25641
Jan J. Cornelissen is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 63, co-authored 389 publications receiving 22197 citations. Previous affiliations of Jan J. Cornelissen include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien,François Guilhot,Richard A. Larson,Insa Gathmann,Michele Baccarani,Francisco Cervantes,Jan J. Cornelissen,Thomas Fischer,Andreas Hochhaus,Timothy P. Hughes,Klaus Lechner,Johan Lanng Nielsen,Philippe Rousselot,Josy Reiffers,Giuseppe Saglio,John D. Shepherd,Bengt Simonsson,Alois Gratwohl,John M. Goldman,Hagop M. Kantarjian,Kerry Taylor,Gregor Verhoef,Ann E. Bolton,Renaud Capdeville,Brian J. Druker +24 more
TL;DR: Imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML and was better tolerated than combination therapy.
Journal ArticleDOI
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker,François Guilhot,Stephen G. O'Brien,Insa Gathmann,Hagop M. Kantarjian,Norbert Gattermann,Michael W. Deininger,Richard T. Silver,John M. Goldman,Richard Stone,Francisco Cervantes,Andreas Hochhaus,Bayard L. Powell,Janice Gabrilove,Philippe Rousselot,Josy Reiffers,Jan J. Cornelissen,Timothy P. Hughes,Hermine Agis,Thea Kolsen Fischer,Gregor Verhoef,John D. Shepherd,Giuseppe Saglio,Alois Gratwohl,Johan Lanng Nielsen,Jerald P. Radich,Bengt Simonsson,Kerry Taylor,Michele Baccarani,Charlene So,Laurie Letvak,Richard A. Larson +31 more
TL;DR: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
Journal ArticleDOI
Acute myeloid leukaemia.
Asim Khwaja,Magnus Björkholm,Rosemary E. Gale,Ross L. Levine,Craig T. Jordan,Gerhard Ehninger,Clara D. Bloomfield,Eli Estey,Alan Kenneth Burnett,Jan J. Cornelissen,David A. Scheinberg,Didier Bouscary,David C. Linch +12 more
TL;DR: A plethora of new agents — including those targeted at specific biochemical pathways and immunotherapeutic approaches — are now in trial based on improved understanding of disease pathophysiology, providing good grounds for optimism, although mortality remains high especially in older patients.
Journal ArticleDOI
Human fetal lymphoid tissue–inducer cells are interleukin 17–producing precursors to RORC + CD127 + natural killer–like cells
Tom Cupedo,Natasha K Crellin,Natalie Papazian,Elwin J. C. Rombouts,Kees Weijer,Jane L. Grogan,Willem E. Fibbe,Jan J. Cornelissen,Hergen Spits,Hergen Spits +9 more
TL;DR: In this article, the authors identify human lymphoid tissue-inducer cells (LTi cells) as lineage-negative RORC+ CD127+ cells with the functional ability to interact with mesenchymal cells through lymphotoxin and tumor necrosis factor.
Journal ArticleDOI
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).
Jeroen J. A. van Kampen,David A. M. C. van de Vijver,Pieter L. A. Fraaij,Bart L. Haagmans,Mart M. Lamers,Nisreen M.A. Okba,Johannes P. C. van den Akker,Henrik Endeman,Diederik Gommers,Jan J. Cornelissen,Rogier A.S. Hoek,Menno M. van der Eerden,Dennis A. Hesselink,Herold J. Metselaar,Annelies Verbon,Jurriaan E. M. de Steenwinkel,Georgina I. Aron,Eric C. M. van Gorp,Sander van Boheemen,Jolanda J.C. Voermans,Charles A. Boucher,Richard Molenkamp,Marion Koopmans,Corine H. GeurtsvanKessel,Annemiek A. van der Eijk +24 more
TL;DR: In this paper, the authors report that infectious virus shedding is detected by virus cultures in 23 of the 129 patients (17.8%) hospitalized with COVID-19, and that the median duration of shedding infectious virus is 8 days post onset of symptoms (IQR 5-11) and drops below 5% after 15.2 days after onset of symptom (95% confidence interval (CI) 13.4-17.2).